Synopsis of recent research by authors named "Rie Yazawa"
- Rie Yazawa's recent research focuses on the pharmacokinetics, safety, and tolerability of candidate biosimilars and novel therapeutic agents in healthy Japanese adult populations, as evidenced by multiple Phase I clinical trials.
- Key findings from studies, including evaluations of biosimilars like CT-P47 and FKB327, demonstrate critical pharmacokinetic equivalence to established reference products, thereby supporting their potential as effective alternatives.
- Yazawa has also contributed to understanding the implications of therapeutic agents in managing conditions like obesity and chronic kidney disease, as shown by investigations into glucagon receptor agonists and the pharmacokinetics of roxadustat influenced by dietary components.
